BioTechne snaps up Exosome Diagnostics in $250M deal

BioTechne snaps up Exosome Diagnostics in $250M deal


Minneapolis-based biotech supplier Bio-Techne Corp. has agreed to pay $250 million, and maybe more, to acquire a promising Boston-area firm that makes precision-medicine technology used to detect cancer without a tissue biopsy. Bio-Techne plans to acquire privately held Exosome Diagnostics, Inc. by early August, using cash on hand and a revolving line of credit.



from Biotech News